OptiBiotix Health (AIM:OPTI), the AIM-listed life sciences company developing gut microbiome and appetite-reduction products, updated investors on its SweetBiotix sugar substitute range.
The company held a shareholder presentation and tasting session on 24 June, where a three-person panel compared SweetBiotix against sugar.
Investors reported a clean taste with no aftertaste and sweetness slightly above that of sugar.
The update follows a November announcement that OptiBiotix had introduced a new enzyme delivering higher yields and a purer, cleaner-tasting product through a simplified one-step manufacturing process that cuts ingredient and production costs.
The company said it has made good progress on the pathway to production and commercialisation set out at the tasting session.
"We are encouraged by the level of interest in SweetBiotix from major partners, including a recent approach from a global beverage company", said Stephen O'Hara, chief executive of OptiBiotix Health.
O'Hara said the new enzyme has reduced manufacturing complexity and widened the pool of potential production partners, giving the company a clearer route to commercial scale despite remaining challenges.
Further progress updates on the commercialisation pathway are expected in due course.
News Intelligence what this means for the company
OptiBiotix reported that a global beverage company has approached it following a June shareholder tasting of SweetBiotix, its bioengineered sugar substitute. The company claims progress on a commercialisation pathway after November's announcement of a new enzyme that simplifies manufacturing, cuts costs, and improves taste—but no deal, timeline, or financial terms have been disclosed, and the company explicitly states 'further progress updates' are only 'expected in due course.'
Interest from a major beverage partner is a validation signal for SweetBiotix's commercial viability, but the absence of a binding agreement, production scale-up timeline, or revenue forecast leaves the pathway to value creation opaque. The company's ability to fund development and reach market will depend on either closing a partnership deal or monetising its minority equity stakes—a dependency that has already required a £675,000 share sale in April.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
